Cargando…

How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR

Diabetic kidney disease (DKD) is one of the most relevant complications of type 2 diabetes and dramatically increases the cardiovascular risk in these patients. Currently, DKD is severely infra-diagnosed, or its diagnosis is usually made at advanced stages of the disease. During the last decade, new...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Carro, Clara, Vergara, Ander, Bermejo, Sheila, Azancot, María A., Sánchez-Fructuoso, Ana I., Sánchez de la Nieta, M. Dolores, Agraz, Irene, Soler, María José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201333/
https://www.ncbi.nlm.nih.gov/pubmed/34198818
http://dx.doi.org/10.3390/jcm10112505
_version_ 1783707794757648384
author García-Carro, Clara
Vergara, Ander
Bermejo, Sheila
Azancot, María A.
Sánchez-Fructuoso, Ana I.
Sánchez de la Nieta, M. Dolores
Agraz, Irene
Soler, María José
author_facet García-Carro, Clara
Vergara, Ander
Bermejo, Sheila
Azancot, María A.
Sánchez-Fructuoso, Ana I.
Sánchez de la Nieta, M. Dolores
Agraz, Irene
Soler, María José
author_sort García-Carro, Clara
collection PubMed
description Diabetic kidney disease (DKD) is one of the most relevant complications of type 2 diabetes and dramatically increases the cardiovascular risk in these patients. Currently, DKD is severely infra-diagnosed, or its diagnosis is usually made at advanced stages of the disease. During the last decade, new drugs have demonstrated a beneficial effect in terms of cardiovascular and renal protection in type 2 diabetes, supporting the crucial role of an early DKD diagnosis to permit the use of new available therapeutic strategies. Moreover, cardiovascular and renal outcome trials, developed to study these new drugs, are based on diverse cardiovascular and renal simple and composite endpoints, which makes difficult their interpretation and the comparison between them. In this article, DKD diagnosis is reviewed, focusing on albuminuria and the recommendations for glomerular filtration rate measurement. Furthermore, cardiovascular and renal endpoints used in classical and recent cardiovascular outcome trials are assessed in a pragmatic way.
format Online
Article
Text
id pubmed-8201333
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82013332021-06-15 How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR García-Carro, Clara Vergara, Ander Bermejo, Sheila Azancot, María A. Sánchez-Fructuoso, Ana I. Sánchez de la Nieta, M. Dolores Agraz, Irene Soler, María José J Clin Med Review Diabetic kidney disease (DKD) is one of the most relevant complications of type 2 diabetes and dramatically increases the cardiovascular risk in these patients. Currently, DKD is severely infra-diagnosed, or its diagnosis is usually made at advanced stages of the disease. During the last decade, new drugs have demonstrated a beneficial effect in terms of cardiovascular and renal protection in type 2 diabetes, supporting the crucial role of an early DKD diagnosis to permit the use of new available therapeutic strategies. Moreover, cardiovascular and renal outcome trials, developed to study these new drugs, are based on diverse cardiovascular and renal simple and composite endpoints, which makes difficult their interpretation and the comparison between them. In this article, DKD diagnosis is reviewed, focusing on albuminuria and the recommendations for glomerular filtration rate measurement. Furthermore, cardiovascular and renal endpoints used in classical and recent cardiovascular outcome trials are assessed in a pragmatic way. MDPI 2021-06-05 /pmc/articles/PMC8201333/ /pubmed/34198818 http://dx.doi.org/10.3390/jcm10112505 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
García-Carro, Clara
Vergara, Ander
Bermejo, Sheila
Azancot, María A.
Sánchez-Fructuoso, Ana I.
Sánchez de la Nieta, M. Dolores
Agraz, Irene
Soler, María José
How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR
title How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR
title_full How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR
title_fullStr How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR
title_full_unstemmed How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR
title_short How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR
title_sort how to assess diabetic kidney disease progression? from albuminuria to gfr
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201333/
https://www.ncbi.nlm.nih.gov/pubmed/34198818
http://dx.doi.org/10.3390/jcm10112505
work_keys_str_mv AT garciacarroclara howtoassessdiabetickidneydiseaseprogressionfromalbuminuriatogfr
AT vergaraander howtoassessdiabetickidneydiseaseprogressionfromalbuminuriatogfr
AT bermejosheila howtoassessdiabetickidneydiseaseprogressionfromalbuminuriatogfr
AT azancotmariaa howtoassessdiabetickidneydiseaseprogressionfromalbuminuriatogfr
AT sanchezfructuosoanai howtoassessdiabetickidneydiseaseprogressionfromalbuminuriatogfr
AT sanchezdelanietamdolores howtoassessdiabetickidneydiseaseprogressionfromalbuminuriatogfr
AT agrazirene howtoassessdiabetickidneydiseaseprogressionfromalbuminuriatogfr
AT solermariajose howtoassessdiabetickidneydiseaseprogressionfromalbuminuriatogfr